Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors

Leukemia and Lymphoma

Volumn 56, Issue 1, 2015, Pages 120-127

  Khoury, H Jean ^a   Cortes, Jorge ^b   Baccarani, Michele ^c   Wetzler, Meir ^d   Masszi, Tamas ^e   Digumarti, Raghunadharao ^f   Craig, Adam ^g   Benichou, Annie Claude ^g   Akard, Luke ^h  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e Szent Laszlo Hospital   (Hungary)

^f NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^g ChemGenex Pharmaceuticals A Wholly Owned Subsidiary of Teva Branded Pharmaceutical Products RandD Inc   (United States)

^h Indiana Blood and Marrow Transplantation   (United States)

Author keywords

Accelerated; Blast; Drug resistance; Myeloid leukemias and dysplasias; Omacetaxine; Pharmacotherapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; HARRINGTONINE DERIVATIVE; HOMOHARRINGTONINE; PROTEIN KINASE INHIBITOR;

ADULT; AGED; CANCER STAGING; CLINICAL TRIAL; DISEASE COURSE; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HARRINGTONINES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922365628     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.889826     Document Type: Article

References (32)

1. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-1061.
2. Kantarjian H, O'Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012; 119: 1981-1987.
3. Palandri F, Castagnetti F, Alimena G, et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica 2009; 94: 205-212.
4. Palandri F, Castagnetti F, Testoni N, et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica 2008; 93: 1792-1796.
5. Giralt SA, Arora M, Goldman JM, et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007; 137: 461-467.
6. Khoury HJ, Kukreja M, Goldman JM, et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant 2012;47:810-816.
7. Jiang Q, Xu LP, Liu DH, et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 2011; 117: 3032-3040.
8. Oyekunle A, Zander AR, Binder M, et al. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Ann Hematol 2012;92:487-496.
9. Luatti S, Castagnetti F, Marzocchi G, et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic inf uence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood 2012;120:761-767.
10. Rea D, Etienne G, Nicolini F, et al. First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. Leukemia 2012; 26: 2254-2259.
11. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-125.
12. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in dif erent subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006;12:7374-7379.
13. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99:3547-3553.
14. Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005; 103: 1659-1669.
15. le Coutre PD, Giles FJ, Hochhaus A, et al. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 2012; 26: 1189-1194.
16. Nicolini FE, Masszi T, Shen Z, et al. Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase or blast crisis. Leuk Lymphoma 2012;53:907-914.
17. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367: 2075-2088.
18. Gambacorti-Passerini C, Cortes JE, Khoury HJ, et al. Safety and ef cacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: update from study SKI-200. J Clin Oncol 2010; 28(15 Suppl.): Abstract 6509.
19. Deininger MWN, Cortes JE, Kim D-W, et al. Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in patients with chronic myeloid leukemia. J Clin Oncol 2013;31(Suppl.): Abstract 7001.
20. Jabbour E, Garcia-Manero G, Cortes J, et al. Twice-daily fudarabine and cytarabine combination with or without gentuzumab ozogamicin is ef ective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast-phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 2012;12:244-251.
21. Tedeschi A, Montillo M, Ferrara F, et al. Treatment of chronic myeloid leukemia in the blastic phase with fudarabine, cytosine arabinoside and G-CSF (FLAG). Eur J Haematol 2000; 64: 182-187.
22. Chen Y, Hu Y, Michaels S, et al. Inhibitory ef ects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 2009;23:1446-1454.
23. Quintas-Cardama A, Kantarjian H, Cortes J. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 2009;115:5382-5393.
24. Tujebajeva RM, Graifer DM, Karpova GG, et al. Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation. FEBS Lett 1989;257:254-256.
25. Wetzler M, Segal D. Omacetaxine as an anticancer therapeutic: what is old is new again. Curr Pharm Des 2011;17:59-64.
26. Levy V, Zohar S, Bardin C, et al. A phase I dose-f nding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. Br J Cancer 2006;95:253-259.
27. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007;109:248-255.
28. Cortes J, Digumarti R, Parikh PM, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol 2013;88:350-354.
29. Cortes J, Lipton JH, Rea D, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 2012;120:2573-2580.
30. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988;61:1441-1446.
31. Cortes J, Kim DW, Rafoux E, et al. Ef cacy and safety of dasatinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008; 22: 2176-2183.
32. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces signif cant hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109:4143-4150.